(Total Views: 696)
Posted On: 07/05/2020 1:10:37 PM
Post# of 154127
Satisfying unmet medical needs:
IMHO this is the card the NP is banking on very heavily and the concerted efforts to:
- unblind m/m and s/c simultaneously
- present a distribution partner
- have an incoming supply of stock
- analyse as many blood samples as possible
CytoDyn will probably present the finsihed results of the s/c study together with the anecdotal evidence of the unfinished s/c patients and argue. If we wait any further treating these anecdotal patients, a few more in the placebo arm will die before we have confirmed data. Do you FDA want to run that risk?
We will have an interesting week ahead of us.
Greetings from Germany
baggo-mh
IMHO this is the card the NP is banking on very heavily and the concerted efforts to:
- unblind m/m and s/c simultaneously
- present a distribution partner
- have an incoming supply of stock
- analyse as many blood samples as possible
CytoDyn will probably present the finsihed results of the s/c study together with the anecdotal evidence of the unfinished s/c patients and argue. If we wait any further treating these anecdotal patients, a few more in the placebo arm will die before we have confirmed data. Do you FDA want to run that risk?
We will have an interesting week ahead of us.
Greetings from Germany
baggo-mh
(1)
(0)
